Condition: Hepatocellular Carcinoma · Sponsor: Shandong New Time Pharmaceutical Co., LTD
There are two studies included in this protocol. One is an open-label Phase Ⅱ study . The other is a multi-center, double-blind, randomized, phase III study .
This description comes directly from the study's public registry record.
Zhou Ai ping, professor · 13691161998 · zhouap1825@126.com
Cai Jian qiang, professor · 010-67781331 · caijianqiang188@sina.com
Always discuss trial participation with your own doctor first.
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | Recruiting |
| Huizhou Central People's Hospital | Guandong, China | Recruiting |
| Jinan Central Hospital | Shandong, China | Recruiting |
| Linyi Cancer Hospital | Shandong, China | Recruiting |
| Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center | Shenzhen, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05408221